person. The hours burden imposed by the pretest will be approximately 8.5 hours (100 respondents 5 minutes for each).

The FTC staff estimates that the survey of 1,000 respondents also will require no more than 5 minutes per person or 83.5 hours (1,000 respondents 5 minutes for each).

Thus, the estimated total hours burden attributable to the telephone survey research is 242 hours (150 + 8.5 + 83.5).

The combined total hours burden attributable to both research projects is 378.5 hours (242 + 136.5).

3. Estimated Cost Burden

The cost per respondent should be negligible. Participation is voluntary and will not require any labor expenditures by respondents nor capital, start-up, operation, maintenance, or other similar costs.

William Blumenthal
General Counsel

[FR Doc. E9–12590 Filed 6–4–08: 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Meeting of the National Biodefense Science Board

AGENCY: Department of Health and Human Services, Office of the Secretary.

ACTION: Notice.

SUMMARY: As stipulated by the Federal Advisory Committee Act, the Department of Health and Human Services is hereby giving notice that the National Biodefense Science Board (NBSB) will be holding a meeting. The meeting is open to the public.

DATES: The meeting will be held on June 18, 2008, from 8:30 a.m. to 5 p.m.


SUPPLEMENTARY INFORMATION: Pursuant to section 319M of the Public Health Service Act (42 U.S.C. 247d–7f) and section 222 of the Public Health Service Act (42 U.S.C. 217a), the Department of Health and Human Services established the National Biodefense Science Board.

The Board shall provide expert advice and guidance to the Secretary on scientific, technical, and other matters of special interest to the Department of Health and Human Services regarding current and future chemical, biological, nuclear, and radiological agents, whether naturally occurring, accidental, or deliberate. The Board may also provide guidance to the Secretary on other matters related to public health emergency preparedness and response.

Topics to be discussed include updates from the Pandemic Influenza Working Group, the Disaster Medicine Working Group, the Markets and Sustainability Working Group, and the U.S. Medical Countermeasure Research and Development Processes for Chemical, Biological, Radiological and Nuclear Agents Working Group. Additionally, the NBSB will discuss preparedness and planning issues related to at-risk populations and pandemic influenza, consider issues related to medical response and preparedness for radiological and nuclear events, and receive an update on the activities of the Homeland Security Presidential Directive #21, Federal Biosurveillance Working Group. The NBSB will also receive a briefing on issues related to the Department of Health and Human Services development of MedKits. This agenda is subject to change as priorities dictate. A tentative schedule will be made available on June 6, 2008 at the NBSB Web site, http://www.hhs.gov/aspr/omspf/nbsb.

Any member of the public interested in presenting oral comments at the meeting may notify the Contact person listed on this notice by June 11, 2008. Interested individuals and representatives of an organization may submit a letter of intent and a brief description of the organization represented. In addition, any interested person may file written comments with the committee. All written comments must be received prior to June 11, 2008 and should be sent by e-mail with “NBSB Public Comment” as the subject line or by regular mail to the Contact person listed above. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the designated contact person.


RADM William C. Vanderwagen, Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services.

[FR Doc. 08–1321 Filed 6–2–08; 2:27pm]
Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. “Collection of information” is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)[2](A)) requires Federal agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document.

With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA’s functions, including whether the information will have practical utility; (2) the accuracy of FDA’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.

Veterinary Feed Directive—21 CFR Part 558 (OMB Control Number 0910-0363)—Extension

With passage of the Animal Drug Availability Act, Congress enacted legislation establishing a new class of restricted feed use drugs called Veterinary Feed Directive (VFD drugs).

The VFD class of drugs may be distributed without involving State pharmacy laws. Although controls on the distribution and use of VFD drugs are similar to controls for prescription drugs regulated under section 503(f) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 503(f), the implementing VFD regulation under section 558.6 (21 CFR 558.6) is tailored to the unique circumstances relating to the distribution of medicated feeds. The content of the VFD is spelled out in the regulation. All distributors of medicated feed containing VFD drugs must notify FDA of their intent to distribute, and the distribution records of all medicated feeds containing VFD must be maintained. The VFD regulation ensures the protection of the public health while enabling animal producers to obtain and use needed drugs as efficiently and cost-effectively as possible.

FDA estimates the burden of this collection of information as follows:

<table>
<thead>
<tr>
<th>21 CFR Section</th>
<th>No. of Respondents</th>
<th>Annual Frequency per Response</th>
<th>Total Annual Responses</th>
<th>Hours per Response</th>
<th>Total Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>558.6(a)(3) through (a)(5)</td>
<td>15,000</td>
<td>25</td>
<td>375,000</td>
<td>.25</td>
<td>93,750</td>
</tr>
<tr>
<td>558.6(d)(1)(i) through (d)(1)(iii)</td>
<td>300</td>
<td>1</td>
<td>300</td>
<td>.25</td>
<td>75</td>
</tr>
<tr>
<td>558.6(d)(1)(iv)</td>
<td>20</td>
<td>1</td>
<td>20</td>
<td>.25</td>
<td>5</td>
</tr>
<tr>
<td>558.6(d)(2)</td>
<td>1,000</td>
<td>5</td>
<td>5,000</td>
<td>.25</td>
<td>1,250</td>
</tr>
<tr>
<td>514.1(b)(9)</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3.00</td>
<td>3</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>16,321</strong></td>
<td></td>
<td></td>
<td><strong>95,083</strong></td>
<td></td>
</tr>
</tbody>
</table>

1 There are no capital costs or operating and maintenance costs associated with this collection of information.

<table>
<thead>
<tr>
<th>21 CFR Section</th>
<th>No. of Recordkeepers</th>
<th>Annual Frequency per Recordkeeping</th>
<th>Total Annual Records</th>
<th>Hours per Record</th>
<th>Total Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>558.6(c)(1) through (c)(4)</td>
<td>112,500</td>
<td>10</td>
<td>1,125,000</td>
<td>.0167</td>
<td>18,788</td>
</tr>
<tr>
<td>558.6(e)(1) through (e)(4)</td>
<td>5,000</td>
<td>75</td>
<td>375,000</td>
<td>.0167</td>
<td>6,263</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>117,500</strong></td>
<td></td>
<td></td>
<td><strong>25,051</strong></td>
<td></td>
</tr>
</tbody>
</table>

1 There are no capital costs or operating and maintenance costs associated with this collection of information.

The estimate of the times required for record preparation and maintenance is based on agency communication with industry and agency records and experience.

Please note that on January 15, 2008, the FDA Division of Dockets Management Web site transitioned to the Federal Dockets Management System (FDMS). FDMS is a Government-wide, electronic docket management system. Electronic comments or submissions will be accepted by FDA only through FDMS at http://www.regulations.gov.


Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E8–12648 Filed 6–4–08; 8:45 am]
BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee for Pharmaceutical Science and Clinical Pharmacology; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.